TrialsgrambetaRCTs are beautiful

EMPEROR-Reduced

2020

Empagliflozin Outcome Trial in Chronic Heart Failure With Reduced EF

In 3,730 patients with HFrEF (EF ≤ 40 %), empagliflozin reduced cardiovascular death or heart-failure hospitalisation compared with placebo.

Result

Efficacy: CV death or HF hospitalisationHR 0.75

Below 1 favours empagliflozin, above 1 favours placebo.

Event rates
Absolute difference
5.3 points

The absolute difference is derived from the event rates.

Also reported: Slower decline in renal function.

Original publication
Subtopic
SGLT2 inhibitors
Design
Double-blind RCT
Relevance
Important: one of several pillars.
Source
Packer M, et al. N Engl J Med. 2020;383(15):1413-1424.doi 10.1056/NEJMoa2022190

Discussion & critique

Confirmed the SGLT2-inhibitor class effect alongside DAPA-HF. No clear mortality signal individually; the pooled HFrEF data show consistent benefit.

Discussed in podcasts